{"id":"NCT00957372","sponsor":"Bial - Portela C S.A.","briefTitle":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy","officialTitle":"Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Clinical Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2009-08-12","resultsPosted":"2013-08-05","lastUpdate":"2014-07-02"},"enrollment":253,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Epilepsy"],"interventions":[{"type":"DRUG","name":"eslicarbazepine acetate","otherNames":["Zebinix"]},{"type":"DRUG","name":"placebo (Part I)","otherNames":[]},{"type":"DRUG","name":"ESL - Open-label Extension (Part II)","otherNames":[]}],"arms":[{"label":"ESL 800 mg daily (Part I)","type":"EXPERIMENTAL"},{"label":"ESL 1200 mg daily (Part I)","type":"EXPERIMENTAL"},{"label":"placebo (Part I)","type":"PLACEBO_COMPARATOR"},{"label":"ESL - Open-label Extension (Part II)","type":"EXPERIMENTAL"}],"summary":"The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period.","primaryOutcome":{"measure":"Seizure Frequency","timeFrame":"12 weeks","effectByArm":[{"arm":"Placebo","deltaMin":7.3,"sd":null},{"arm":"ESL 800 mg","deltaMin":5.7,"sd":null},{"arm":"ESL 1200 mg","deltaMin":5.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":1,"countries":["Portugal"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Dizziness","Somnolence","Headache","Vomiting","Nausea"]}}